Results 81 to 90 of about 3,216,105 (293)
Adverse reactions of biological therapies in patients with psoriasis [PDF]
, 2017 Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp.Georgescu, Simona R., Limbău, Alexandra M., Mitran, Cristina I., Mitran, Mădălina I., Sârbu, Maria I., Tampa, Mircea +5 morecore +4 more sourcesUse of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. [PDF]
, 2014 Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies, Ahmed, S, Harrison, A, Magan, T, Sofat, N, Vargas, M +4 morecore +2 more sourcesImpact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria
Arthritis &Rheumatology, EarlyView.Objective
To evaluate the applicability of the 2016 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) macrophage activation syndrome (MAS) classification criteria in patients with Still disease and systemic juvenile idiopathic arthritis ...Remco G. A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J. H. Schatorjé, Esther P. A. H. Hoppenreijs, Joost F. Swart, Marc H. A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert +14 morewiley +1 more sourcePsoriatic arthritis: A retrospective study of 162 patients [PDF]
Vojnosanitetski Pregled, 2005 Aim. The aim of our study was to determine the prevalence of psoriatic arthritis in the patients with psoriasis and to analyze retrospectively the results of a 34-year multidisciplinary management of the patients with psoriatic arthritis. Methods.Pavlica Ljiljana, Perić-Hajzler Zorica, Jovelić Aleksandra, Šekler Boris, Damjanović Milorad +4 moredoaj +1 more sourceComparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis [PDF]
, 2017 Objective: In agreement with EULAR recommendations, a DMARD in combination with a biotherapy is the reference treatment because of the superior long-term clinical and radiographic outcomes. Methotrexate (MTX) is the cornerstone of combination therapy but Corominas, Héctor, Díaz-Torné, César, Hernández Miguel, María Victoria, Llobet, Josep Maria, Magallares, Berta, Narváez García, Francisco Javier, Nolla Solé, Joan Miquel, Reina, Delia, Rodríguez de la Serna, Arturo, Sanmartí Sala, Raimon +9 morecore +1 more sourceEfficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial
Arthritis &Rheumatology, Accepted Article.Objective
Despite availability of biologics and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital +13 morewiley +1 more sourceBiologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
Therapeutics and Clinical Risk Management, 2022 Takeo Hata,1 Atsushi Hirata,2 Ryosuke Ota,2 Keiko Hosohata,3 Masami Nishihara,1 Masashi Neo,1 Takahiro Katsumata1 1Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan; 2Department of Pharmacy, Kindai ...Hata T, Hirata A, Ota R, Hosohata K, Nishihara M, Neo M, Katsumata T +6 moredoaj Biologics registers in RA: methodological aspects, current role and future applications [PDF]
, 2017 The beginning of the 21st century saw a biopharmaceutical revolution in the treatment of inflammatory rheumatic diseases, particularly rheumatoid arthritis. The fast-evolving use of biologic therapies highlighted the need to develop registers at national A Finckh, A Strangfeld, A Strangfeld, A Strangfeld, A Zink, A Zink, C Gabay, C Gabay, C Lahaye, C Sjöwall, D Plant, D Salmon-Ceron, E Lie, E Uitz, EH Ibfelt, Elena Nikiphorou, F Atzeni, F Iannone, FB Pallavicini, H Canhão, HK Choi, J Askling, J Askling, J Askling, J Askling, J Askling, J Askling, J Askling, J Listing, J Sode, J-E Gottenberg, JB Galloway, JD Greenberg, JE Fonseca, JE Gottenberg, JJ Gomez-Reino, JR Curtis, K Chatzidionysiou, K Chatzidionysiou, K Hellgren, K Watson, Kimme L. Hyrich, KL Hyrich, KL Hyrich, KL Hyrich, KL Hyrich, KL Hyrich, L Dreyer, L Kearsley-Fleet, L Silva-Fernández, L Virkki, LE Kristensen, LK Mercer, LK Mercer, M Kihara, M Lunt, M Neovius, M Østergaard, MA Machado, Maya H. Buch, MK Söderlin, ML Hetland, ML Hetland, MM Soliman, MM Soliman, P Emery, P Raaschou, PP Tak, R van Vollenhoven, RF van Vollenhoven, RF van Vollenhoven, S James, S Saevarsdottir, SMM Verstappen, SMM Verstappen, TK Kvien, W Kievit, WG Dixon, WG Dixon, WG Dixon, X Mariette, X Mariette +81 morecore +1 more sourceAmerican College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Arthritis &Rheumatology, EarlyView.Objective
Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.Arsene M. Mekinian, Sophie Georgin‐Lavaille, Marcela A. Ferrada, Sinisa Savic, Matthew J. Koster, Olivier Kosmider, Thibault Comont, Mael Heilblig, Juan I. Arostegui, Annmarie Bosco, Rim Bourguiba, Katherine R. Calvo, Catherine Cargo, Chiara Cattaneo, François Chasset, Henrique Coelho, Corrado Campochiaro, Francesca Crisafulli, Stephanie Ducharme‐Benard, Raquel Faria, Franco Franceschini, Micol Frassi, Emma M. Groarke, Carmelo Gurnari, Yervand Hakobyan, Yvan Jamilloux, Ciprian Jurcut, Yohei Kirino, Austin Kulasekararaj, Hiroyoshi Kunimoto, Lauren M. Madigan, Heřman F. Mann, Chiara Marvisi, Marcin Milchert, Sara Morais, Katja Sockel, Francesco Muratore, Hideaki Nakajima, Mrinal M. Patnaik, Luísa Regadas, Marie Robin, Abraham Rutgers, Carlo Salvarani, Anthony M. Sammel, Joerg Seebach, Pierre Sujobert, Alessandro Tomelleri, Geoffrey Urbanski, Frédéric Vandergheynst, Romana Vieira, David S. Viswanatha, Ewa Więsik‐Szewczyk, Elisa Diral, Benjamin Terrier, Bhavisha A. Patel, Pierre Fenaux, Peter C. Grayson, David B. Beck, on behalf of the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases, Heřman Mann, Benjamin Terrier, François Chasset, Sophie Georgin Lavialle, Alessandro Tomelleri, Campochiaro Corrado, Carlo Salvarani, Francesca Crisafulli, Franco Franceschini, Micol Frassi, Yohei Kirino, Ewa Więsik‐Szewczyk, Marcin Milchert, Raquel Faria, Ciprian Jurcut, Joerg Seebach, Sinisa Savic, David Beck, Lauren Madigan, Matthew Koster, Patnaik Mrinal, Olivier Kosmider, Pierre Sujobert, Juan I. Arostegui, Catherine Cargo, David Viswanatha, Yervand Hagopian, Mael Heilblig, Pierre Fenaux, Thibault Comont, Bruno Alessandro, Chiara Cattaneo, Elisa Diral, Sara Morais, Austin Kulasekarara, Emma Groarke, Katherine Calvo, Patel Bhavisha, Anthony Sammel, Arsene Mekinian, Benjamin Terrier, Marie Robin, Sophie Georgin Lavialle, Katja Sockel, Yvan Jamilloux, Carmelo Gurnari, Henrique Coelho, Romana Vieira, Rim Bourguiba, Marcela Ferrada, Peter Grayson +111 morewiley +1 more source
